Latest Period
Q4 2025
Security Snapshot
Tarsus Pharmaceuticals, Inc. - Common Stock (TARS) Institutional Ownership
CUSIP: 87650L103
13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026
Institutions Reporting
245
Shares (Excl. Options)
44,051,121
Price
$81.88
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- TARS on Nasdaq
- Shares outstanding
- 42,450,857
- Price per share
- $72.65
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 44,051,121
- Total reported value
- $3,606,395,142
- % of total 13F portfolios
- 0%
- Share change
- -1,686,793
- Value change
- -$100,796,094
- Number of holders
- 245
- Price from insider filings
- $72.65
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- TARS - Tarsus Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 87650L103.
- 245 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 245 to 50 between Q4 2025 and Q1 2026.
- Reported value moved from $3,606,395,142 to $144,317,327.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 245 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 87650L103?
CUSIP 87650L103 identifies TARS - Tarsus Pharmaceuticals, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 87650L103:
Significant Owners of Tarsus Pharmaceuticals, Inc. - Common Stock (TARS) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 8.1% | $134,159,372 | 3,424,180 | RTW Investments, LP | 30 Jun 2025 | |||
| BlackRock, Inc. | 7.4% | $153,770,784 | 3,092,735 | BlackRock, Inc. | 31 Mar 2025 | |||
| Deep Track Capital, LP | 7.1% | +25% | $178,290,000 | +$38,453,587 | 3,000,000 | +27% | Deep Track Capital, LP | 30 Sep 2025 |
| MORGAN STANLEY | 4.7% | $96,628,483 | 1,943,453 | Morgan Stanley | 31 Mar 2025 | |||
| Cowen Financial Products LLC | 4.9% | $94,926,816 | 1,909,228 | Cowen Financial Products LLC | 31 Dec 2024 | |||
| TANG CAPITAL MANAGEMENT LLC | 2.8% | -52% | $89,776,771 | -$95,634,047 | 1,188,624 | -52% | TANG CAPITAL MANAGEMENT, LLC | 31 Dec 2025 |
As of 31 Dec 2025, 245 institutional investors reported holding 44,051,121 shares of Tarsus Pharmaceuticals, Inc. - Common Stock (TARS). This represents 104% of the company’s total 42,450,857 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Tarsus Pharmaceuticals, Inc. - Common Stock (TARS) together control 81% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.9% | 3,790,557 | +0.29% | 0.01% | $310,370,807 |
| RTW INVESTMENTS, LP | 7.9% | 3,335,320 | +5% | 2.7% | $273,096,002 |
| Deep Track Capital, LP | 7.1% | 3,004,034 | +0.13% | 5.6% | $245,970,304 |
| Paradigm Biocapital Advisors LP | 6% | 2,562,154 | -3.9% | 5.6% | $209,789,170 |
| VANGUARD GROUP INC | 5.7% | 2,399,560 | +5.6% | 0% | $196,475,972 |
| JENNISON ASSOCIATES LLC | 5.3% | 2,230,069 | -14% | 0.11% | $182,598,052 |
| MORGAN STANLEY | 4.8% | 2,040,742 | +6.7% | 0.01% | $167,095,971 |
| JANUS HENDERSON GROUP PLC | 4.5% | 1,930,325 | +34% | 0.07% | $158,062,427 |
| TANG CAPITAL MANAGEMENT LLC | 2.8% | 1,188,624 | -52% | 4.8% | $97,324,533 |
| Driehaus Capital Management LLC | 2.8% | 1,172,427 | +14% | 0.65% | $95,998,323 |
| Assenagon Asset Management S.A. | 2.7% | 1,127,730 | -9.6% | 0.14% | $92,338,532 |
| Invesco Ltd. | 2.4% | 1,012,357 | +8% | 0.01% | $82,891,790 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 947,763 | +0.35% | 0% | $77,616,160 |
| STATE STREET CORP | 2.2% | 929,059 | -0.76% | 0% | $76,071,351 |
| LORD, ABBETT & CO. LLC | 2% | 855,645 | -13% | 0.21% | $70,060,000 |
| BANK OF AMERICA CORP /DE/ | 1.8% | 758,106 | +41% | 0% | $62,073,719 |
| Frazier Life Sciences Management, L.P. | 1.7% | 728,644 | -38% | 1.6% | $59,661,371 |
| FMR LLC | 1.5% | 647,114 | +2860% | 0% | $52,985,671 |
| D. E. Shaw & Co., Inc. | 1.4% | 615,156 | +2.8% | 0.04% | $50,368,973 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1.4% | 584,686 | 0% | 0.07% | $47,874,000 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.2% | 518,780 | +15% | 0% | $42,479,000 |
| TORONTO DOMINION BANK | 1.2% | 510,253 | -17% | 0.07% | $41,779,516 |
| Clearbridge Investments, LLC | 1.2% | 506,089 | -11% | 0.03% | $41,438,557 |
| Ensign Peak Advisors, Inc | 1.1% | 474,050 | -1.7% | 0.07% | $38,815,214 |
| LOOMIS SAYLES & CO L P | 1% | 441,873 | +13% | 0.04% | $36,180,561 |
Institutional Holders of Tarsus Pharmaceuticals, Inc. - Common Stock (TARS) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 2,058,623 | $144,317,327 | +$13,889,476 | $70.15 | 50 |
| 2025 Q4 | 44,051,121 | $3,606,395,142 | -$100,796,094 | $81.88 | 245 |
| 2025 Q3 | 44,893,892 | $2,667,774,204 | -$49,024,662 | $59.43 | 219 |
| 2025 Q2 | 46,131,357 | $1,868,819,935 | +$92,954,236 | $40.51 | 204 |
| 2025 Q1 | 43,564,795 | $2,238,109,644 | +$155,550,097 | $51.37 | 191 |
| 2024 Q4 | 40,257,261 | $2,228,992,305 | -$65,425,283 | $55.37 | 192 |
| 2024 Q3 | 43,391,345 | $1,426,965,052 | +$102,534,235 | $32.89 | 161 |
| 2024 Q2 | 40,066,753 | $1,089,006,566 | +$6,596,629 | $27.18 | 147 |
| 2024 Q1 | 39,323,641 | $1,429,414,516 | +$260,798,405 | $36.35 | 155 |
| 2023 Q4 | 32,126,860 | $650,570,328 | +$49,625,202 | $20.25 | 114 |
| 2023 Q3 | 29,793,106 | $529,411,112 | +$139,188,159 | $17.77 | 105 |
| 2023 Q2 | 21,435,682 | $387,312,097 | +$39,178,138 | $18.07 | 92 |
| 2023 Q1 | 20,057,814 | $252,130,256 | -$6,023,437 | $12.57 | 73 |
| 2022 Q4 | 20,531,051 | $300,987,054 | +$5,059,618 | $14.66 | 67 |
| 2022 Q3 | 20,489,091 | $350,771,070 | +$9,266,431 | $17.12 | 72 |
| 2022 Q2 | 19,980,650 | $291,715,823 | +$98,791,820 | $14.60 | 70 |
| 2022 Q1 | 13,210,299 | $222,212,113 | -$29,618,514 | $16.82 | 50 |
| 2021 Q4 | 13,072,993 | $294,217,317 | +$4,316,413 | $22.50 | 43 |
| 2021 Q3 | 12,869,541 | $277,366,339 | -$12,449,066 | $21.55 | 43 |
| 2021 Q2 | 13,061,656 | $378,528,053 | +$8,240,890 | $28.98 | 44 |
| 2021 Q1 | 12,761,893 | $410,350,129 | -$213,790 | $32.23 | 41 |
| 2020 Q4 | 12,759,585 | $523,637,183 | +$523,637,191 | $41.33 | 39 |